3B Blackbio DX Ltd
Incorporated in 2011, 3B BlackBio Dx Ltd manufactures and exports PCR based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, and agrochemical-based products[1]
- Market Cap ₹ 1,361 Cr.
- Current Price ₹ 1,586
- High / Low ₹ 2,100 / 1,151
- Stock P/E 23.7
- Book Value ₹ 347
- Dividend Yield 0.25 %
- ROCE 25.8 %
- ROE 19.4 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
- Company has a good return on equity (ROE) track record: 3 Years ROE 16.8%
Cons
- Earnings include an other income of Rs.20.4 Cr.
- Dividend payout has been low at 7.82% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of BSE Healthcare BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22 | 19 | 17 | 16 | 23 | 23 | 29 | 227 | 81 | 62 | 74 | 96 | 129 | |
| 21 | 18 | 16 | 14 | 18 | 16 | 20 | 77 | 44 | 33 | 41 | 46 | 73 | |
| Operating Profit | 1 | 1 | 2 | 3 | 5 | 7 | 9 | 150 | 37 | 29 | 33 | 50 | 56 |
| OPM % | 6% | 7% | 9% | 16% | 23% | 31% | 32% | 66% | 46% | 47% | 44% | 52% | 44% |
| 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 7 | 7 | 13 | 15 | 20 | |
| Interest | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| Profit before tax | 0 | 0 | 0 | 1 | 5 | 7 | 10 | 152 | 43 | 35 | 44 | 64 | 75 |
| Tax % | 14% | 23% | 23% | 19% | 24% | 25% | 23% | 25% | 26% | 27% | 28% | 25% | |
| 0 | 0 | 0 | 1 | 3 | 5 | 8 | 114 | 32 | 26 | 32 | 48 | 58 | |
| EPS in Rs | 0.59 | 0.36 | 0.51 | 1.76 | 5.35 | 8.18 | 10.24 | 151.66 | 42.89 | 34.55 | 37.40 | 55.57 | 66.92 |
| Dividend Payout % | -0% | -0% | -0% | 17% | 9% | 6% | 7% | 6% | 24% | 8% | 8% | 7% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 27% |
| 3 Years: | 6% |
| TTM: | 33% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 70% |
| 5 Years: | 44% |
| 3 Years: | 14% |
| TTM: | 20% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 67% |
| 5 Years: | 39% |
| 3 Years: | 57% |
| 1 Year: | -16% |
| Return on Equity | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 30% |
| 3 Years: | 17% |
| Last Year: | 19% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 9 | 9 | 9 | 9 |
| Reserves | 4 | 4 | 4 | 5 | 12 | 16 | 25 | 125 | 146 | 185 | 214 | 260 | 290 |
| 7 | 8 | 8 | 9 | 6 | 6 | 4 | 2 | 3 | 2 | 1 | 0 | 0 | |
| 7 | 7 | 6 | 6 | 6 | 8 | 9 | 59 | 37 | 19 | 24 | 27 | 42 | |
| Total Liabilities | 24 | 25 | 24 | 26 | 30 | 36 | 45 | 194 | 192 | 214 | 248 | 296 | 341 |
| 4 | 4 | 3 | 3 | 4 | 4 | 4 | 5 | 7 | 8 | 7 | 7 | 17 | |
| CWIP | -0 | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | -0 |
| Investments | -0 | -0 | -0 | -0 | -0 | -0 | 1 | 59 | 93 | 92 | 117 | 156 | 160 |
| 20 | 21 | 21 | 22 | 26 | 32 | 40 | 130 | 93 | 114 | 123 | 132 | 163 | |
| Total Assets | 24 | 25 | 24 | 26 | 30 | 36 | 45 | 194 | 192 | 214 | 248 | 296 | 341 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 1 | 1 | 2 | 4 | 7 | 98 | 37 | 20 | 27 | 43 | |
| -0 | -0 | -0 | -0 | -1 | -1 | -1 | -70 | -28 | 15 | -20 | -33 | |
| 0 | -0 | -1 | -0 | 0 | -1 | 1 | -2 | -15 | -5 | -4 | -3 | |
| Net Cash Flow | 0 | -0 | 0 | -0 | 1 | 2 | 7 | 26 | -6 | 30 | 3 | 7 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 213 | 262 | 283 | 321 | 259 | 290 | 252 | 56 | 136 | 200 | 179 | 138 |
| Inventory Days | 120 | 145 | 143 | 175 | 164 | 141 | 124 | |||||
| Days Payable | 189 | 218 | 203 | 186 | 69 | 66 | 28 | |||||
| Cash Conversion Cycle | 144 | 188 | 223 | 310 | 259 | 290 | 252 | 56 | 136 | 296 | 253 | 235 |
| Working Capital Days | 144 | 175 | 205 | 247 | 253 | 287 | 275 | 65 | 162 | 241 | 215 | 169 |
| ROCE % | 7% | 7% | 7% | 13% | 24% | 28% | 31% | 162% | 27% | 19% | 21% | 26% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
7 Feb - Submission of Advertisement Clipping of the extract of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended …
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
6 Feb - Earning Concall under Regulation 30 of the SEBI (LODR) Regulations. 2015.
- Announcement under Regulation 30 (LODR)-Investor Presentation 6 Feb
- Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2025 6 Feb
-
Board Meeting Outcome for Outcome Of Board Meeting
6 Feb - Approved unaudited Q3 and 9M results to Dec 31, 2025; consolidated 9M PAT Rs4,903.08 lakh.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Feb 2026TranscriptAI SummaryPPT
-
Nov 2025TranscriptAI SummaryPPT
-
Aug 2025Transcript PPT REC
-
May 2025TranscriptAI SummaryPPT
-
Feb 2025TranscriptAI SummaryPPT
-
Nov 2024TranscriptAI SummaryPPT
-
Aug 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024TranscriptAI SummaryPPT
-
Nov 2023TranscriptAI SummaryPPT
-
Aug 2023TranscriptAI SummaryPPT
-
May 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
-
Nov 2022TranscriptAI SummaryPPT
-
Sep 2022TranscriptAI SummaryPPT
-
Aug 2022TranscriptAI SummaryPPT
-
May 2022TranscriptAI SummaryPPT
-
Feb 2022TranscriptAI SummaryPPT
-
Nov 2021TranscriptAI SummaryPPT
-
Sep 2021TranscriptAI SummaryPPT
-
Jul 2021TranscriptAI SummaryPPT
-
Jun 2021TranscriptAI SummaryPPT
-
Feb 2021TranscriptAI SummaryPPT
-
Feb 2021TranscriptAI SummaryPPT
-
Nov 2020TranscriptAI SummaryPPT
-
Sep 2020TranscriptAI SummaryPPT
-
Jul 2020TranscriptAI SummaryPPT
-
Jun 2020TranscriptAI SummaryPPT
-
Feb 2020TranscriptAI SummaryPPT
-
Nov 2019TranscriptAI SummaryPPT
-
Jul 2019TranscriptAI SummaryPPT
-
May 2019TranscriptAI SummaryPPT
-
Jan 2019TranscriptAI SummaryPPT
-
Nov 2018TranscriptAI SummaryPPT
-
Aug 2018TranscriptAI SummaryPPT
-
May 2018TranscriptAI SummaryPPT
-
Feb 2018TranscriptAI SummaryPPT
-
Nov 2017TranscriptAI SummaryPPT
-
Jul 2017TranscriptAI SummaryPPT
-
Feb 2017TranscriptAI SummaryPPT
Business Segments[1][2]
A) Diagnostics Business (81% of FY23 revenue)
3BDL is part of an Indo-Spanish JV and was formed by amalgamation with its parent company Kilpest India Limited. Company is an ISO 13485:2016 certified, GMP-compliant biotech R&D organization and is engaged in the design, development, manufacturing, and commercialization of Rapid tests, PCR-based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, NGS-based Molecular Diagnostic Kit